Valeur202020212022202320242025Total du passif1.44 B1.34 B1.78 B1.17 B906.9 M796 MTotal des capitaux propres1.45 B1.62 B1.38 B649.3 M482.8 M522.6 MTotal du passif et des capitaux propres2.88 B2.96 B3.17 B1.82 B1.39 B1.32 BDette totale874.8 M841 M1.41 B860.2 M663.7 M572.1 MDette nette253.5 M264.9 M763.2 M748.5 M564.2 M366.7 M
Emergent BioSolutions Inc
Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.
Among the company's products are the controversial BioThrax, the only anthrax vaccine licensed by the U.S. Food and Drug Administration and Narcan for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid.
During the COVID-19 pandemic, Emergent BioSolutions also produced Johnson & Johnson/Janssen and Oxford–AstraZeneca vaccines at one of its plants; however, this was marked by contamination and other production issues, and millions of doses of vaccine had to be discarded.